Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide

  • E. Keller
  • G. Hoppe-Seyler
  • R. Mumm
  • P. Schollmeyer


After rapid intravenous injection of furosemide 40 mg (Fu), plasma levels were determined in 7 healthy volunteers, 8 patients with liver cirrhosis with ascites and 7 patients with end-stage renal disease (ESRD). The diuretic response was evaluated by measuring the urinary excretion of sodium and potassium and the urine volume. The mean elimination half life (tF1/2+) of Fu averaged 51±7.7 (±SD) min in healthy subjects, 52±7.7 min in cirrhosis and 200±57 min in ESRD. The non-renal clearance (Clnr) in healthy subjects (56±28 ml/min) corresponds to the total plasma clearance in functionally anephric patients (54±18 ml/min). In cirrhosis there was no significant change in the disposition parameters of Fu in comparison to the healthy volunteers, but there was a significant reduction in urine sodium and volume, whereas potassium excretion remained unchanged. Fu “excretion rate — response” curves showed diminished tubular sensitivity to Fu in cirrhosis.

Key words

furosemide cirrhosis end-stage renal disease pharmacokinetic diuretic response urine potassium urine sodium 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexander WA, Levine DF, Branch RA, Hartog M (1977) Urinary sodium/potassium ratio and response to diuretics in resistant oedema. Postgrad Med J 53: 117–121PubMedCrossRefGoogle Scholar
  2. Andreasen F, Jakobsen P (1974) Determination of furosemide in blood plasma and its binding to proteins in normal plasma from patients with acute renal failure. Acta Pharmacol Toxicol 35: 49–57CrossRefGoogle Scholar
  3. Andreasen F, Mikkelsen E (1977) Distribution, elimination and effects of furosemide in normal subjects and in patients with heart failure. Eur J Pharmacol 12: 15–22CrossRefGoogle Scholar
  4. Beermann B, Dalen E, Lindström B (1977) Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22: 70–78PubMedGoogle Scholar
  5. Benet L (1979) Pharmacokinetics, pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm 7: 1–27PubMedCrossRefGoogle Scholar
  6. Branch R, Roberts C, Homeida M, Levine D (1977) Determinants of response to furosemide in normal subjects. Br J Clin Pharmacol 4: 121–127PubMedGoogle Scholar
  7. Brater C, Chennavasin P, Seiwell R, Beck J (1980) Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther 28: 182–186PubMedCrossRefGoogle Scholar
  8. Chennavasin P, Seiwell R, Brater DC, Liang WM (1979) Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 16: 187–195PubMedGoogle Scholar
  9. Cutler R, Forrey A, Christopher T, Kimpel B (1974) Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 15: 588–596PubMedGoogle Scholar
  10. Cutler R, Blair A (1979) Clinical pharmacokinetics of furosemide. Clin Pharmacokinet 4: 279–296PubMedCrossRefGoogle Scholar
  11. Dettli L (1976) Drug dosage in renal disease. Clin Pharmacokinet 1: 126–134PubMedGoogle Scholar
  12. Hoppe-Seyler G (1980) Pharmakokinetik und Pharmakodynamik von Diuretika. Diuretika, edition medizin, Weinheim, pp 103–111Google Scholar
  13. Huang CM, Atkinson A, Levin M, Quintanilla A (1974) Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther 16: 659–666PubMedGoogle Scholar
  14. Kind H, Schmid E (1969) Über die Harnausscheidung von Furosemid bei Gesunden und Kranken mit Leberzirrhose. Pharmacol Clin 2: 221–226CrossRefGoogle Scholar
  15. Kleinfelder H (1963) Experimentelle Untersuchungen und klinische Erfahrungen mit einem neuen Diuretikum. Dtsch Med Wochenschr 88: 1695–1702PubMedCrossRefGoogle Scholar
  16. Lawrence J, Ansari F, Elliott L, Summer J, Brunton F, Whiting B, Whitesmith R (1978) Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther 23: 558–565PubMedGoogle Scholar
  17. Lindström B, Molander M (1974) Gas chromatographic determination of furosemide in plasma using an extractive alkylation technique and an electron capture detector. J Chromatogr 101: 219–221PubMedCrossRefGoogle Scholar
  18. Lopez-Novoa JM, Rengel MA, Rodicio JL, Hernando L (1977) A micropuncture study of salt and water retention in chronic experimental cirrhosis. Am J Physiol 232: 315–318Google Scholar
  19. Naranja C, Pontigo E, Valdenegro C, Gonzales G, Ruiz I, Busto U (1979) Furosemide-induced adverse reactions in cirrhosis of the liver. Clin Pharmacol Ther 25: 154–160Google Scholar
  20. Odlind B, Beermann B (1980) Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 27: 784–790PubMedCrossRefGoogle Scholar
  21. Prandotta J, Pruitt AW (1975) Furosemide binding to human albumin in plasma of nephrotic children. Clin Pharmacol Ther 17: 159–166Google Scholar
  22. Rane A, Villeneuve J, Stone W, Nies A, Wilkinson G, Branch R (1978) Plasma binding and disposition of furosemide in the nephrotic syndrom and in uremia. Clin Pharmacol Ther 24: 199–207PubMedGoogle Scholar
  23. Rupp W, Heidland A, Neuhaus G (1970) Pharmakokinetik von Furosemid bei normaler und eingeschränkter Nierenfunktion. Freiburger Tagung über Nephrologie 1970. Thieme, Stuttgart, p 24Google Scholar
  24. Tilstone W, Fine A (1978) Furosemide kinetics in renal failure. Clin Pharmacol Ther 23: 644–650PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • E. Keller
    • 1
  • G. Hoppe-Seyler
    • 1
  • R. Mumm
    • 1
  • P. Schollmeyer
    • 1
  1. 1.Medizinische UniversitätsklinikFreiburgFederal Republic of Germany

Personalised recommendations